Last reviewed · How we verify
BDP HFA
BDP HFA is a inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.
BDP HFA is a inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | BDP HFA |
|---|---|
| Also known as | BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) Nasal Aerosol, QNASL® |
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Beclomethasone dipropionate (BDP) is a corticosteroid delivered via hydrofluoroalkane (HFA) propellant in metered-dose inhaler form. It acts locally in the airways to suppress inflammatory responses, reduce mucus production, and decrease airway hyperresponsiveness. The HFA formulation provides improved lung deposition compared to older chlorofluorocarbon (CFC) propellants.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Nervousness
- Oral candidiasis
- Throat irritation
Key clinical trials
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
- Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR® (PHASE1)
- Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574) (PHASE2)
- An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects (PHASE2)
- Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR) (PHASE3)
- Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis (PHASE3)
- A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma (PHASE3)
- A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BDP HFA CI brief — competitive landscape report
- BDP HFA updates RSS · CI watch RSS
- Teva Branded Pharmaceutical Products R&D, Inc. portfolio CI